POMDOCTOR LIMITED (POM) AI Stock Analysis
POM AI stock analysis summary
AI ResearchPOMDOCTOR LIMITED operates an online medical services and chronic disease management platform in China. Over the trailing twelve months, the company generated revenue of $410.4M alongside an operating margin of -125.9%. Its balance sheet as of June 30, 2026, reflects negative shareholders' equity of -$69.4M and total debt of $66.4M against cash of $1.9M.
- Market cap
- $5.9M
- Revenue (TTM)
- $410.4M
- P/E
- —
- 1Y return
- -85.7% S&P 500 16.8%
- Avg. target
- —
Bull case
- Revenue expanded from $215.4M in FY2021 to $399.9M in FY2025, reflecting a 5-year compound annual growth rate of 23.1%.
- Quarterly revenue grew 6.0% year-over-year in the latest quarter ending June 30, 2026, reaching trailing twelve-month revenue of $410.4M.
- The stock has rebounded 114.2% year-to-date through October 16, 2026, trading 12.0% above its 200-day average.
Bear case
- The company remains deeply unprofitable, reporting a trailing twelve months profit margin of -90.2% and an operating margin of -125.9%.
- Balance sheet liquidity is constrained with cash of $1.9M against total debt of $66.4M and negative shareholders' equity of -$69.4M as of June 30, 2026.
- Operating cash flow deteriorated to -$148.5M and free cash flow was -$149.5M in FY2025.
What POMDOCTOR LIMITED does
Pomdoctor Limited, through its subsidiaries, operates an online B2C portal to sell pharmaceutical products. Founded in 2010 and headquartered in Guangzhou, China, the company develops an online medical services platform for chronic diseases in China. It focuses on chronic disease management and pharmaceutical services, connecting patients to doctors and pharmaceutical products. In addition, the company is involved in internet hospital operations and a pharmaceutical supply chain that links users, pharmacies, suppliers, medical professionals, and other healthcare participants. It has 165 employees.
Growth and profitability
From FY2021 to FY2025, annual revenue increased from $215.4M to $399.9M, achieving a 5-year revenue CAGR of 23.1% from FY2020 to FY2025. Annual revenue expanded 52.5% in FY2021, 13.9% in FY2022, 24.3% in FY2023, 12.4% in FY2024, and 16.7% in FY2025. However, profitability remained negative, with net income moving from -$188.4M in FY2021 to -$212.6M in FY2025. For FY2025, gross margin was 13.1% and operating margin was -29.1%. In the trailing twelve months ending June 30, 2026, revenue totaled $410.4M, with quarterly revenue growth YoY of 6.0%, a profit margin of -90.2%, and an operating margin of -125.9%.
Balance sheet and cash flow
As of June 30, 2026, the company held cash and short-term investments of $1.9M against total debt of $66.4M, resulting in net debt of $64.5M. Total assets stood at $11.2M, while shareholders' equity was -$69.4M, indicating negative equity. The company reported a current ratio of 0.35. Cash flow from operations was -$148.5M in FY2025, and free cash flow was -$149.5M. For FY2025, capital expenditures were $1.0M, while research and development expenses were $12.9M.
Valuation and performance
POMDOCTOR LIMITED has a market capitalization of $5.9M and an enterprise value of $74.9M. Its price-to-sales multiple is 0.0x, compared to 4.1x for the median of its US-listed Healthcare peers. Its EV to revenue stands at 1.3x. In the stock market, the shares closed at $0.63 on October 16, 2026, up 114.2% year-to-date and 12.0% above their 200-day average. Over the past year, the stock fell 85.7%, while the S&P 500 (SPY) returned 16.8%.
What analysts expect
There are no analyst ratings, price targets, or earnings estimates available for POMDOCTOR LIMITED. For the trailing twelve months ending June 30, 2026, diluted earnings per share were -$6.84, following an eps of -$1.49 reported in FY2024. The shares closed at $0.63 on October 16, 2026, trading between a 52-week low of $0.06 and a 52-week high of $6.43. No scheduled next earnings report date is provided.
Key risks and what to watch
- The current ratio of 0.35 as of June 30, 2026, highlights short-term liquidity pressure given total debt of $66.4M.
- Operating margin weakened significantly from -7.5% in FY2024 to -29.1% in FY2025 and reached -125.9% on a trailing twelve months basis.
- The stock experienced severe volatility, falling 85.7% over the past one-year period while trading down from its 52-week high of $6.43.
- Annual net losses widened to -$212.6M in FY2025, contributing to a return on assets of -352.1% over the trailing twelve months.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this POM AI stock analysis
This page is an AI-written research summary of POMDOCTOR LIMITED (POM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: POM income statement, POM balance sheet, POM key metrics, POM chart. See the POM stock overview for the latest quote and news.
POM AI stock analysis FAQ
What does POMDOCTOR LIMITED do?
POMDOCTOR LIMITED operates an online medical services and B2C pharmaceutical platform focused on chronic disease management in China. It links patients, physicians, pharmacies, and suppliers through an internet hospital and supply chain network.
What was POM's revenue growth in FY2025?
In FY2025, revenue reached $399.9M, representing year-over-year growth of 16.7%. From FY2020 to FY2025, the company delivered a 5-year revenue CAGR of 23.1%.
Does POM pay a dividend?
No dividend information is reported for POM. The company generated free cash flow of -$149.5M in FY2025 and does not pay a regular dividend.
What is POM's debt and cash position?
As of June 30, 2026, POMDOCTOR LIMITED held $1.9M in cash and short-term investments compared to $66.4M in total debt, leaving net debt of $64.5M. Shareholders' equity was negative at -$69.4M.
How has POM stock performed recently?
As of October 16, 2026, POM shares closed at $0.63. While the stock has gained 114.2% year-to-date, it fell 85.7% over the trailing one-year period.